• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>Western Asset Emerging Mkts Income

Western Asset Emerging Mkts Income

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase III Studies in Multiple Sclerosis

    Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase III Studies in Multiple Sclerosis

  2. A Makeover At The 'Other' Merck

    A Makeover At The 'Other' Merck

  3. Merck KGaA, Darmstadt, Germany: Innovative Fertility Technologies Gavi and Geri of Partner Genea Biomedx Receive CE Mark

    Merck KGaA, Darmstadt, Germany: Innovative Fertility Technologies Gavi and Geri of Partner Genea Biomedx Receive CE Mark

  4. Consumerization Drives Growth at Merck Consumer Health

    Consumerization Drives Growth at Merck Consumer Health

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.